Literature DB >> 19863851

Low-risk prostate cancer and low testosterone: what are the acceptable alternatives?

Mark Soloway1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19863851     DOI： 10.1007/s11934-009-0078-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


× No keyword cloud information.
  30 in total

Review 1.  Clinical practice. Localized prostate cancer.

Authors:  Patrick C Walsh; Theodore L DeWeese; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

2.  Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Olga M Calof; Atam B Singh; Martin L Lee; Anne M Kenny; Randall J Urban; Joyce L Tenover; Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-11       Impact factor: 6.053

3.  Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.

Authors:  Michael F Sarosdy
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

4.  Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice.

Authors:  Mark S Litwin; Sheldon Greenfield; Eric P Elkin; Deborah P Lubeck; Jeanette M Broering; Sherrie H Kaplan
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

5.  Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer.

Authors:  M Ribeiro; P Ruff; G Falkson
Journal:  Am J Clin Oncol       Date:  1997-12       Impact factor: 2.339

6.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Authors:  H Ballentine Carter; Patrick C Walsh; Patricia Landis; Jonathan I Epstein
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

Review 7.  The role of testosterone replacement therapy following radical prostatectomy.

Authors:  Mohit Khera; Larry I Lipshultz
Journal:  Urol Clin North Am       Date:  2007-11       Impact factor: 2.241

8.  Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.

Authors:  Robert Abouassaly; Brian R Lane; J Stephen Jones
Journal:  Urology       Date:  2008-04       Impact factor: 2.649

Review 9.  Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

Authors:  Joel M Kaufman; R James Graydon
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

10.  Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.

Authors:  Felix K-H Chun; Nazareno Suardi; Umberto Capitanio; Claudio Jeldres; Sascha Ahyai; Markus Graefen; Alexander Haese; Thomas Steuber; Andreas Erbersdobler; Francesco Montorsi; Hartwig Huland; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2008-05-15       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.